Comparison of commercial 5-aminolevulinic acid (Gliolan®) and the pharmacy-compounded solution fluorescence in glioblastoma

This publication has 42 references indexed in Scilit:

• Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin
  British Journal of Cancer, 2012
• -aminolevulinic acid-induced protoporphyrin IX concentration correlates with histopathologic markers of malignancy in human gliomas: the need for quantitative fluorescence-guided resection to identify regions of increasing malignancy
  Neuro-Oncology, 2011
• An extent of resection threshold for newly diagnosed glioblastomas
  Journal of Neurosurgery, 2011
• Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between δ-aminolevulinic acid–induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters
  Journal of Neurosurgery, 2011
• Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy
  British Journal of Cancer, 2011
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
  Nature, 2010
• 5‐Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement
  Cancer, 2010
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
  The Lancet Oncology, 2009
• Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
  The Lancet Oncology, 2006
• Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid: Dependence on cell density, cell size and cell cycle
  International Journal of Cancer, 1998